News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
235,424 Results
Type
Article (5509)
Company Profile (24)
Press Release (229891)
Multimedia
Podcasts (3)
Webinars (4)
Section
Business (83016)
Career Advice (575)
Deals (15200)
Drug Delivery (12)
Drug Development (19541)
Employer Resources (32)
FDA (3788)
Job Trends (4075)
News (121946)
Policy (7952)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (315)
Accelerated approval (6)
Adcomms (4)
Allergies (15)
Alliances (15014)
ALS (38)
Alzheimer's disease (299)
Antibody-drug conjugate (ADC) (40)
Approvals (3893)
Artificial intelligence (81)
Autoimmune disease (29)
Automation (5)
Bankruptcy (98)
Best Places to Work (3003)
Biosimilars (46)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (102)
Cancer (895)
Cardiovascular disease (111)
Career advice (488)
Career pathing (4)
CAR-T (64)
CDC (2)
Cell therapy (167)
Cervical cancer (5)
Clinical research (17105)
Collaboration (361)
Compensation (373)
Complete response letters (8)
COVID-19 (360)
CRISPR (13)
C-suite (340)
Cystic fibrosis (29)
Data (1384)
Denatured (1)
Depression (22)
Diabetes (97)
Diagnostics (2139)
Digital health (8)
Diversity (1)
Diversity, equity & inclusion (14)
Drug discovery (31)
Drug pricing (29)
Drug shortages (2)
Duchenne muscular dystrophy (36)
Earnings (42942)
Editorial (6)
Employer branding (7)
Employer resources (34)
Events (39523)
Executive appointments (430)
FDA (4544)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (348)
Gene editing (26)
Generative AI (5)
Gene therapy (104)
GLP-1 (170)
Government (489)
Guidances (197)
Healthcare (5241)
HIV (10)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (41)
Immuno-oncology (7)
Indications (16)
Infectious disease (387)
Inflammatory bowel disease (37)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (33)
Interviews (73)
IPO (7940)
IRA (4)
Job creations (1155)
Job search strategy (431)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (110)
Leadership (7)
Legal (2584)
Liver cancer (21)
Longevity (2)
Lung cancer (93)
Lymphoma (71)
Machine learning (3)
Management (10)
Manufacturing (143)
MASH (50)
Medical device (3959)
Medtech (3969)
Mergers & acquisitions (7666)
Metabolic disorders (245)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (13)
Neuroscience (545)
NextGen: Class of 2026 (1772)
Non-profit (779)
Now hiring (6)
Obesity (99)
Opinion (38)
Ovarian cancer (26)
Pain (27)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (53)
Patient recruitment (102)
Peanut (6)
People (25464)
Pharmaceutical (7)
Pharmacy benefit managers (21)
Phase 1 (5044)
Phase 2 (7322)
Phase 3 (6056)
Pipeline (2006)
Policy (25)
Postmarket research (687)
Preclinical (1971)
Press Release (66)
Prostate cancer (58)
Psychedelics (3)
Radiopharmaceuticals (110)
Rare diseases (185)
Real estate (1907)
Recruiting (9)
Regulatory (5698)
Reports (17)
Research institute (321)
Resumes & cover letters (115)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (57)
Series B (58)
Sickle cell disease (10)
Special edition (2)
Spinal muscular atrophy (35)
Sponsored (7)
Startups (1029)
Stomach cancer (1)
Supply chain (14)
Tariffs (8)
The Weekly (2)
Vaccines (93)
Venture capital (9)
Weight loss (40)
Women's health (7)
Worklife (1)
Date
Today (15)
Last 7 days (149)
Last 30 days (538)
Last 365 days (9042)
2026 (812)
2025 (9179)
2024 (11194)
2023 (13317)
2022 (18838)
2021 (19951)
2020 (18562)
2019 (13634)
2018 (10510)
2017 (10200)
2016 (9321)
2015 (12262)
2014 (9697)
2013 (7790)
2012 (8420)
2011 (8896)
2010 (8739)
Location
Africa (209)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (2)
Asia (11914)
Australia (1720)
California (3577)
Canada (1143)
China (168)
Colorado (144)
Connecticut (165)
Delaware (72)
Europe (25891)
Florida (544)
Georgia (68)
Idaho (24)
Illinois (175)
India (14)
Indiana (108)
Iowa (9)
Japan (166)
Kansas (36)
Kentucky (17)
Louisiana (9)
Maine (51)
Maryland (357)
Massachusetts (2824)
Michigan (105)
Minnesota (203)
Mississippi (1)
Missouri (33)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1056)
New Mexico (5)
New York (822)
North Carolina (481)
North Dakota (4)
Northern California (1868)
Ohio (117)
Oklahoma (5)
Oregon (6)
Pennsylvania (618)
Puerto Rico (1)
Rhode Island (23)
South America (361)
South Carolina (17)
Southern California (1326)
Tennessee (61)
Texas (486)
United States (12510)
Utah (112)
Virginia (86)
Washington D.C. (20)
Washington State (298)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
235,424 Results for "cvs caremark corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies
May 1, 2025
·
9 min read
Biotech Beach
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.
July 17, 2023
·
5 min read
Press Releases
CVS Health Names David Joyner Chair of the Board of Directors
November 21, 2025
·
2 min read
Press Releases
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 30, 2024
·
12 min read
Press Releases
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
November 10, 2025
·
3 min read
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
Earnings
Lilly Unfazed as CVS Picks Novo’s Side in Obesity Market Battle
Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.
May 1, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
October 20, 2025
·
12 min read
Business
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report
CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis.
July 12, 2024
·
2 min read
·
Tristan Manalac
Pharmacy benefit managers
House Oversight Chair Calls on PBM Execs to Correct Testimonies
The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.
August 29, 2024
·
2 min read
·
Tristan Manalac
1 of 23,543
Next
